Artimplant receives go-ahead to market implant for thumb arthritis in Australia

By Angela McDaniels

Seattle, Dec. 15 - Artimplant AB said it has received approval to market the Artelon TMC Spacer for the treatment of thumb base osteoarthritis in Australia.

New York-based Small Bone Innovations LLC will market the product.

The implant is made of Artelon, a long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue.

The Artelon TMC Spacer also buffers the bone-on-bone contact that results from osteoarthritic joint degeneration, preserves the bone anatomy of the hand, reduces pain and is implanted in a fast procedure that requires no general anesthesia, the company said.

Further, results from a pilot study showed that patients with the Artelon TMC Spacer experienced significantly better grip strength compared to a control group of patients treated with tendon interposition arthroplasty, the company said.

The study was published in the March 2005 issue of American Journal of Hand Surgery.

Artimplant is a biomaterials company based in Stockholm that develops degradable surgical implants for orthopedics, odontology and reconstructive surgery.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.